HOME >> MEDICINE >> NEWS
Combined contrast enhanced MRI shows promise

Combined contrast enhanced (CCE) MRI, in which two contrast agents are used together, permits accurate non-invasive staging of liver fibrosis in non-alcoholic fatty liver disease (NAFLD), according to a new study by researchers from the University of California, San Diego.

For the study, the researchers reviewed 26 patients with NAFLD who underwent CCE MRI. Using a five-point scale, the researchers found that the staging of the NAFLD on CCE MRI closely matched the staging of NAFLD using conventional pathology.

According to the researchers, the prevalence of NAFLD is increasing in western nations and is a major health problem affecting both children and adults. It is a common cause of cirrhosis in American adults and the most common cause in children.

The definitive method of diagnosis and staging is liver biopsy, but it has several limitations, say the researchers. It is invasive, costly, has risks and only samples about 1/50,000th of the liver. "This sampling issue is important because the pathological processes that affect the NAFLD liver are not evenly distributed throughout, so that tiny changes in needle placement will result in potentially large changes in biopsy interpretation. Because of these limitations, alternative methods such as CCE MR need to be developed," said Claude Sirlin, MD, lead author of the study.

"Except for CCE MR, all other experimental techniques rely on surrogate or indirect markers of fibrosis. CCE MR attempts to directly visualize fibrosis by using two contrast agents with complementary mechanisms, iron particles to darken the background liver and gadolinium to brighten the fibrosis," said Dr. Sirlin, "Gadolinium alone and iron particles alone are not adequate for visualization of fibrosis, unless the fibrosis is extremely advanced. However, when given together, the agents show fibrosis with high clarity," he added.

The combined use of two or more complementary contrast agents is uncommon in r
'"/>

Contact: Necoya Lightsey
necoya@arrs.org
604-647-7413
American Roentgen Ray Society
1-May-2006


Page: 1 2

Related medicine news :

1. Combined molecular-targeted and hormonal therapies offer promise in treating ovarian cancer
2. Combined imaging approach may provide better identification of difficult-to-diagnose brain clots
3. Combined therapies may boost immune response and long-term protection against brain tumors
4. Combined liver-kidney transplant beneficial for patients with dual organ disease
5. Combined treatment cuts inflammatory cells in chronic obstructive pulmonary disease
6. Combined MRI and mammography more effective at detecting breast cancer in high-risk women
7. Fluorescence diffuse optical tomography provides high contrast, 3-D look at breast cancer
8. MRI contrast agent can detect heart attack in the making
9. High-resolution imaging with contrast agent shows promise in osteoarthritis research
10. Using contrast enhanced sonography improves diagnosis of liver and spleen injuries
11. Reducing contrast material injection in elderly patients can lower cost of exam and risks

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/9/2016)... Fort Lee, NJ (PRWEB) , ... December 09, ... ... the 2016 Founders Ball at The Pierre Hotel in New York, NY, on ... 700 friends, benefactors, dignitaries and physicians attended the annual event, which raised over ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... Insights beginning January 1, 2017. The name change aligns the entire company ... and improving health care quality. , “We are very proud of the achievements ...
(Date:12/8/2016)... ... 2016 , ... ZyDoc , a New York-based medical ... Capture Methods for Input to Electronic Health Records: A Comparative Usability Study” has ... usability study demonstrate that a dictation-based method (“NLP Entry”) using ZyDoc’s MediSapien™ natural ...
(Date:12/8/2016)... ... ... With the increasing demand for dental implants, the National Association of Dental ... dentists and patients about the safety issues related to dental restorations. According to the ... is projected to reach $6.4 billion in 2018 with more than 30 million Americans ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... continuity to its innovative Unified Instance Manager architecture, meeting the needs of ... new version optimizes the unattended auto-dialing system without agents, Presence Robodialer, provides ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... Global Interventional Radiology Market: Scope and ... radiology market analyzes the current and future prospects ... executive summary, including a market snapshot that provides ... The research is a combination of primary and ... our research efforts along with information collected from ...
(Date:12/8/2016)... 8, 2016  Eli Lilly and Company (NYSE: ... phase 3 EXPEDITION3 trial at the 9 th ... disclosed, solanezumab did not meet the primary endpoint in ... in people with mild dementia due to Alzheimer,s disease ... solanezumab for the treatment of mild dementia due to ...
(Date:12/8/2016)... , Dec. 8, 2016 Bodycad ... patents for improving the accuracy, reproducibility and speed ... in long and small bone orthopaedic applications. These ... to creating personalized orthopaedic restorations based on each ... orthopaedic restorations, the company harnesses the world,s first ...
Breaking Medicine Technology:
Cached News: